PDA

View Full Version : EDAP (MC $56 M) FDA approval for Prostate Cancer Cure in 1Q 2014 =500%++ Potential !!



Barchart
06-23-2014,
A LIFETIME OPPRTUNITY HERE GUYS ...Your opp to load up before the Investors discover this Goldmine !

This Undiscovered Gem is brutally Cheap and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .

FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA

EDAP

Market Cap: $56 M
Cash: $10 M
Price: $2,50
DEBT FREE

Shares Out: 21,7 M

EDAP seeks FDA approval of its Ablatherm HIFU treatment for prostate cancer

http://www.youtube.com/watch?v=MQzaEhf7c9Y


EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study
Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer

http://investor.edap-tms.com/releasedetail.cfm?ReleaseID=765946

Ablatherm? HIFU: A non-invasive treatment for prostate cancer

http://www.examiner.com/article/ablatherm-hifu-a-non-invasive-treatment-for-prostate-cancer

Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.

Marc Oczachowski, EDAP?s chief executive officer, continued, ?Therapeutic ultrasound is gradually gaining ground in cancer treatment approach. We clearly see a growing interest in minimally invasive focal therapies for cancer tumors. Our 20 years expertise in the treatment of localized prostate cancer using HIFU has long been demonstrated and we are excited to further participate in the development of such new projects aiming at improving cancer drug delivery. While we expand our expertise in HIFU to further applications, we remain fully focused on developing our HIFU technology and adapt it to the current focal therapy trend to treat prostate cancers. We believe that the focal therapy approach represents a unique opportunity for Ablatherm HIFU to become the gold standard of treatment for prostate cancer.?

DaveLandry
06-23-2014,
Hello


Once we break the 200 MA at $3.13 then we will move quickly over $4 and to new 52W high . Market Cap of $59 M is still ridiculous GL



Interview with CEO (Sept.25)
http://www.equities.com/media-gallery/188-edap-tms-s-a-nasdaq-edap?category_id=67



10 Best Safest Stocks To Watch For 2014
Wednesday, October 2, 2013
http://beststocksfor2018.blogspot.de/2013/10/10-best-safest-stocks-to-watch-for-2014.html

Some Slides from last Rodman Presentation (august 25)

http://wsw.com/webcast/rrshq23/edap/3__Slide16.jpg

http://wsw.com/webcast/rrshq23/edap/3__Slide17.jpg

http://wsw.com/webcast/rrshq23/edap/3__Slide10.jpg

http://wsw.com/webcast/rrshq23/edap/3__Slide12.jpg

Attached Files:

likesmoney01
06-23-2014,
ADCOM on July 30 ...I think EDAP has the potential to run 50-100% just before ADCOM and could hit $8-10 on positive outcome .US approval would drive EDAP deep into Profitability .



EDAP's Ablatherm-HIFU FDA Panel Meeting Confirmed for July 30, 2014
http://finance.yahoo.com/news/edaps-ablatherm-hifu-fda-panel-123000701.html


http://www.cancerfactorfiction.com/prostate-cancer/hifu-success-rates/

http://www.hifu.ca HIFU has high success rates with the 700 patients treated at the Maple Leaf HIFU clinic. Over 300,000 patients have been treated worldwide by HIFU, with 10 years of documented success for treating prostate cancer with Ablatherm HIFU ? High Intensity Focused Ultrasound.